Intranasal Lidocaine for Primary Headache Management in Emergency Department; a Clinical Trial

Hassan Barzegari, Hassan Motamed, Behrad Ziapour, Majid Hajimohammadi, Mina Kadkhodazadeh, Hassan Barzegari, Hassan Motamed, Behrad Ziapour, Majid Hajimohammadi, Mina Kadkhodazadeh

Abstract

Introduction: Most of the headache cases only require pain management in emergency department (ED). The present study aimed to evaluate the efficacy of intranasal lidocaine in this regard.

Method: In this clinical trial, adult patients with primary headache were randomly treated with 7.5 mg intravenous (IV) chlorpromazine and 1 ml intranasal lidocaine 2% (treatment) or normal saline 0.9% (placebo), and were compared 5, 15, and 30 minutes later regarding success rate using SPSS 21.

Result: 100 patients were assigned to either treatment or placebo group. Number needed to treat of intranasal lidocaine at 5, 15, and 30 minutes were 4 (95% CI: 2.2 - 6.6), 3 (95% CI: 1.7 - 3.5), and 4 (95% CI: 2.3 - 15.9), respectively. These measures for absolute risk reduction were 30 (95% CI: 15.2 - 44.8), 44 (95% CI: 28.7 - 59.3), and 26 percent (95% CI: 6.3 - 44.3), respectively. Pain relapse occurred in 16% of treatment and 11% of control group within 1 hour of treatment (p = 0.402).

Conclusion: It seems that, intranasal lidocaine along with IV chlorpromazine could result in more successful and faster management of primary headaches in ED.

Keywords: Pain management; administration; intranasal; lidocaine; migraine disorders; tension-type Headache.

Figures

Figure 1
Figure 1
Pain severity at the baseline and 5, 15, and 30 minutes after treatment in lidocaine and placebo groups based on visual analogue scale (VAS).

References

    1. Go S. Nontraumatic headaches in the Emergency Department: a systematic approach to diagnosis and controversies in two" big ticket" entities. Missouri medicine. 2008;106(2):156–61.
    1. Edvinsson L. Pathophysiology of primary headaches. Current pain and headache reports. 2001;5(1):71–8.
    1. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS drugs. 2004;18(10):671–85.
    1. Van Vliet J, Bahra A, Martin V, Ramadan N, Aurora S, Mathew N, et al. Intranasal sumatriptan in cluster headache Randomized placebo-controlled double-blind study. Neurology. 2003;60(4):630–3.
    1. Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Archives of neurology. 2006;63(11):1537–42.
    1. Diamond S, Freitag F, Phillips S, Bernstein J, Saper J. Intranasal Civamide for the Acute Treatment of Migraine Headache. Cephalalgia. 2000;20(6):597–602.
    1. Costa A, Pucci E, Antonaci F, Sances G, Granella F, Broich G, et al. The effect of intranasal cocaine and lidocaine on nitroglycerin‐induced attacks in cluster headache. Cephalalgia. 2000;20(2):85–91.
    1. Robbins L. Intranasal Lidocaine for Cluster Headache. Headache: The Journal of Head and Face Pain. 1995;35(2):83–4.
    1. Mohammadkarimi N, Jafari M, Mellat A, Kazemi E, Shirali A. Evaluation of efficacy of intra-nasal lidocaine for headache relief in patients refer to emergency department. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2014;19(4):331.
    1. Generali J, Cada DJ. Intranasal lidocaine: Migraine headaches. Hospital Pharmacy. 2001;36(2):192–223.
    1. Blanda M, Rench T, Gerson LW, Weigand JV. Intranasal lidocaine for the treatment of migraine headache: a randomized, controlled trial. Academic Emergency Medicine. 2001;8(4):337–42.
    1. Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized trial and open‐label follow‐up. Headache: The Journal of Head and Face Pain. 1999;39(8):543–51.
    1. Djupesland PG, Messina JC, Mahmoud RA. Breath Powered Nasal Delivery: A New Route to Rapid Headache Relief. Headache: The Journal of Head and Face Pain. 2013;53:72–84.

Source: PubMed

3
Sottoscrivi